AI assistant
CAMBIUM BIO LIMITED — Capital/Financing Update 2019
Aug 29, 2019
64666_rns_2019-08-29_7541ac87-45cc-426d-b5db-4c66a15e9c3c.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
30 August 2019
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
Non Renounceable Rights Issue Results and Shortfall Notification
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, advises that its partially underwritten non-renounceable rights issue of one New Share for every six shares held, at an issue price of $0.08 closed as scheduled on 27 August 2019.
Regeneus advises that it received valid acceptances for 7,751,973 New Shares (approx. $620,000), with a shortfall remaining of 31,937,872 New Shares.
New Shares associated with the acceptances above are scheduled to be issued to shareholders on Tuesday, 3 September 2019.
The shortfall of 31,937,872 New Shares is partially underwritten to the extent of 22,500,000 New Shares ($1,800,000) by directors. Of this underwritten amount $1,400,000 will be applied to repayment of existing loan funding provided to Regeneus by the directors. The underwriting arrangements are further described in Regeneus’ announcement released on 1 August 2019, and also in Section 1.6 of the Entitlement Booklet.
New Shares associated with the underwriting above are also scheduled to be issued to the underwriters on Tuesday, 3 September 2019.
The shortfall following the underwriting is 9,437,872 New Shares ( Shortfall Shares ). The directors of Regeneus reserve the right, subject to the requirements of the Corporations Act and the ASX Listing Rules, to place any Shortfall Shares within 3 months of the closing date at the directors’ discretion and at a price not less than the Offer Price.
ENDS
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology. http://www.regeneus.com.au
Contact for further information:
Investors
Sandra McIntosh Company Secretary and Investor Relations Regeneus Ltd T: +61 2 9499 8010 E: [email protected]
25 Bridge Street, Pymble, NSW 2073 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358